BACKGROUND: Pediatric solid organ transplant recipients have a 100 to 200 times higher risk of non-Hodgkin lymphoma (NHL) than the general pediatric population. Consequently, transplant-related NHL may contribute considerably to the pediatric NHL burden in the United States. METHODS: A cohort study using a linkage between the US transplant registry and 16 cancer registries was conducted. Cancer incidence rates were calculated for people less than 20 years old in the transplant and general populations. Rates were applied to transplant registry and US census data to estimate pediatric NHL counts for transplant recipients and the general population. RESULTS: During 1990-2012, an estimated 22,270 NHLs were diagnosed in US children and adolescents; they included 628 cases diagnosed in transplant recipients. Thus, 2.82% of pediatric NHL diagnoses in the general population (95% confidence interval [CI], 2.45%-3.19%) occurred in transplant recipients. Among transplant recipients, the most common subtypes were diffuse large B-cell lymphoma (DLBCL; 64.5% of cases) and Burkitt lymphoma (BL; 8.6%). For DLBCL and BL, transplant recipients contributed 7.62% (95% CI, 6.35%-8.88%) and 0.87% (95% CI, 0.51%-1.23%) of diagnoses, respectively. The proportion of NHLs that occurred in transplant recipients was highest among children less than 5 years old (4.46%; 95% CI, 3.24%-5.69%) and in more recent calendar years (3.73% in 2010-2012; 95% CI, 2.07%-5.39%). DLBCL patterns were similar, with transplant recipients contributing 19.78% of cases among children less than 5 years old (95% CI, 12.89%-26.66%) and 11.4% of cases in 2010-2012 (95% CI, 5.54%-17.28%). CONCLUSIONS: Among children and adolescents, solid organ transplant recipients contribute a substantial fraction of NHL diagnoses, particularly DLBCL diagnoses. This fraction has increased over time. Prevention efforts targeted toward this group could reduce the overall pediatric NHL burden.
INTRODUCTION
Non-Hodgkin lymphoma (NHL) is one of the most frequently diagnosed cancers in children and adolescents in the United States: it is responsible for 6% to 8% of cancer diagnoses among persons under the age of 20 years.
1,2 However, NHL is still rare in the US pediatric population, with approximately 1000 cases diagnosed annually and with an incidence of less than 1.5 cases per 100,000 person-years. 2 Pediatric solid organ transplant recipients have a 100 to 200 times higher NHL risk than the general pediatric population. 3, 4 Epstein-Barr virus (EBV) can transform and immortalize B lymphocytes, and this can lead to the development of lymphoma. 5 Although a small minority of the NHLs diagnosed in the general population are attributable to EBV, 6, 7 most NHLs in transplant recipients are positive for EBV. 8, 9 The extremely high NHL risk for transplant recipients is largely attributable to the use of immunosuppressant medications to prevent graft rejection, which results in poor immune control of EBV. 5, 10, 11 In particular, a lack of immune control can make transplant recipients with no prior EBV exposure particularly susceptible to NHL development after a primary EBV infection. 3, 5, 12 Because transplantation strongly increases the risk, NHL is responsible for the majority of cancer diagnoses in pediatric transplant recipients. 3, 4 The NHL risk is especially high in the first year after transplantation. 13, 14 Higher risk is also associated with a younger age at transplantation and transplantation of the intestine, heart, or lung. 3, 12 Because of the exceedingly high risk among pediatric transplant recipients in comparison with the general population, transplant-related NHLs may contribute considerably to the overall NHL burden in US children and adolescents. Importantly, the number of children and adolescents living with a functioning transplant is increasing over time in the United States, 15 and this could have a growing impact on the NHL burden. In the current study, we estimated the contribution of solid organ transplantation to NHLs among US children and adolescents; we used information on the NHL incidence in the transplant population, the NHL incidence in the general population, and the number of US pediatric transplant recipients.
MATERIALS AND METHODS
The Transplant Cancer Match (TCM) study linked the US transplant registry (Scientific Registry of Transplant Recipients [SRTR]) with 16 cancer registries (California [1988 (California [ -2012 , Colorado , Connecticut , Florida , Georgia [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] , Hawaii , Iowa , Illinois , Kentucky [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] , Michigan , North Carolina [1990 Carolina [ -2010 , New Jersey , New York , Texas [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] , Utah , and the Seattle-Puget Sound area of Washington ), which covered geographic areas including 45% of the US transplant population. 16 We included all pediatric transplant recipients less than 20 years old at the time of transplantation, and this is consistent with the age range typically used to describe childhood and adolescent cancers in the general population. 2 The TCM study was approved by human subjects review committees at the National Cancer Institute and, as required, by participating cancer registries.
For transplant recipients in the TCM study undergoing transplantation in this age range, the atrisk time for cancer started at the last of the following: the transplantation date, the start of the cancer registry coverage, or 1990. Although 1987 is the first year of data in the SRTR, 1990 was the first year when at least 500 pediatric transplant recipients were alive in the TCM study, and this allowed a precise estimation of the NHL risk. The at-risk time ended at the first of the following: 20th birthday, death, graft failure, loss to follow-up in the SRTR, or end of cancer registry coverage (the latest year of cancer registry coverage was 2012). Cancer diagnoses after the age of 20 years were not included because the purpose of this study was to quantify the contributions of transplant recipients to the NHL burden among individuals who were less than 20 years old at diagnosis. The person-time for the general population less than 20 years old was estimated on the basis of yearly census estimates within the same geographic regions covered by the TCM cancer registries. The total person-time for transplant recipients was divided by the person-time for the general population to calculate the proportion of time contributed by transplant recipients; this measures the prevalence of the transplant condition in the population.
On the basis of NHL diagnoses linked from the TCM cancer registries, we calculated NHL incidence rates for the pediatric transplant population within the following strata: sex, attained age group, race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, non-Hispanic Asian/Pacific Islander, or other), attained calendar year, transplanted organ (kidney, liver, heart and/or lung [heart/lung], intestine, or multiple and/or other [multiple/other]), and time since transplantation (within the first year or after the first year). To estimate total NHL counts in the US pediatric transplant population, we then applied the rates to the entire US pediatric transplant population in the SRTR. NHL rates among children and adolescents in the general population were calculated from data from the same TCM cancer registries by the use of all NHL diagnoses that occurred in people less than 20 years old. Rates stratified by sex, attained age group, race, calendar year, and transplanted organ were applied to the total US census population to obtain total NHL counts among people less than 20 years old.
Transplant pediatric NHL counts were divided by total pediatric NHL counts to calculate the proportion occurring in the pediatric transplant population. Proportions were calculated overall and by age, calendar period, and sex. We also calculated the proportion of pediatric NHLs that occurred in subgroups of transplant recipients based on the organ type and time since transplantation. For each proportion estimate, 95% confidence intervals (CIs) were calculated under the assumption that transplant NHL counts followed a Poisson distribution. 17 We repeated analyses for the most common NHL subtypes in pediatric transplant recipients: diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). Within each column, the white section shows the proportion of the general population in each age group composed of recipients who were within the first year after transplantation, whereas the black section shows the proportion of recipients who were more than 1 year from transplantation.
RESULTS
Of the 21,418 pediatric transplant recipients in the TCM study, 54% were male, 34% were less than 5 years old at transplantation, and 52% were non-Hispanic white (Table 1 ). The majority of the transplants occurred during 2000-2012. The most commonly transplanted organ was the kidney (47%), which was followed by the liver (30%), heart/lung (20%), and intestine (1%); other organ transplants made up the remaining fraction (3%). Half of the recipients had an unknown EBV serostatus at transplantation (Table 1) , but among those with a known serostatus, 44% were EBV-seronegative. The median follow-up after transplantation was 3.3 years.
The prevalence of transplant recipients among children and adolescents in the general population was very small (0.0110% overall), but it increased more than 4-fold over time, with recipients making up 0.0035% of this population in 1990 versus 0.0159% in 2012 (Fig. 1A ). The prevalence grew over time for each organ type, but the increases were largest for liver recipients (0.0011% of the population in 1990 vs 0.0058% in 2012) and kidney recipients (0.0020% vs 0.0058%). The prevalence was highest in older age groups (0.0158% among 18-to 19-year-olds; Fig. 1B ), but the prevalence of recipients in the first year after transplantation was greatest among children less than 2 years old (0.0035%).
During 1990-2012, there were 10,451 pediatric NHL diagnoses in cancer registry areas, and 279 of these diagnoses occurred among transplant recipients ( Table 2 ). In the general population, the most common subtypes were DLBCL (25% of cases), BL (24%), and precursor cell lymphoblastic lymphoma (20%). Among NHLs diagnosed in transplant recipients, 65% were DLBCL, and 9% were BL, whereas there were no cases of precursor cell lymphoblastic lymphoma. In comparison with cases in the general population, a larger proportion of transplant NHLs were among children less than 5 years old and were diagnosed in later calendar years ( Table 2 ).
In the general population less than 20 years old, the NHL incidence was 1.19 cases per 100,000 person-years (95% CI, 1.12-1.27; Table 3 ). Among transplant recipients in this age range, the incidence was 257 times higher at 306 cases per 100,000 person-years (95% CI, 271-344). On the basis of these rates, we estimated that 22,270 NHLs were diagnosed in US children and adolescents during 1990-2012. Of these, an estimated 628 NHL diagnoses occurred among transplant recipients (or 2.82% of all pediatric NHL diagnoses; 95% CI, 2.45%-3.19%). Table 3 presents the proportion of NHL diagnoses in transplant recipients for various subgroups and illustrates the contributions to each estimate from the prevalence of transplant recipients in the general population, the transplant recipient NHL incidence, and the general population NHL incidence. The NHL incidence was lower in girls than boys in the general population, whereas the NHL incidence was similar for girls and boys in the transplant population. Consequently, transplant recipients contributed a larger proportion of the NHLs in girls versus boys (4.07% vs 2.21%). In the general population, the NHL incidence increased with age, whereas the incidence in the transplant population was highest in children less than 5 years old. Accordingly, the proportion of NHLs in transplant recipients was highest among children less than 5 years old (4.46%; 95% CI, 3.24%-5.69%). The proportion of NHL diagnoses occurring in transplant recipients increased over calendar time from 1.66% of all diagnoses during 1990-1994 (95% CI, 0.94%-2.38%) to 3.73% of diagnoses during 2010-2012 (95% CI, 2.07%- 
5.39%
). This trend reflected the rising prevalence of transplant recipients over time.
Because the kidney was the most frequently transplanted organ, the largest fraction of transplant NHL diagnoses occurred in kidney recipients, who were followed by heart/lung recipients, who had a particularly high NHL risk. In the general population, kidney recipients alone contributed 0.95% of all NHL diagnoses (95% CI, 0.74%-1.16%, Table 3 ), whereas heart/lung recipients alone contributed 0.90% of diagnoses (95% CI, 0.69%-1.11%). Even though the majority of the time contributed by transplant recipients occurred more than a year after transplantation, a similar proportion of NHLs occurred in the first year after transplantation and subsequently because the NHL incidence was particularly high among transplant recipients during the first year.
In comparison with NHL overall, transplant recipients made up a much larger proportion of general population DLBCL cases (7.62%; 95% CI, 6.35%-8.88%; Table 4 ). Patterns for DLBCL were similar to those for NHL overall, with the highest proportions among girls (9.82%), among children less than 5 years old (19.78%), and in later calendar years (11.41% during 2010-2012). Kidney and heart/lung recipients contributed the most DLBCL cases (2.62% from kidney recipients and 2.48% from heart/lung recipients) in comparison with recipients of other organs. The majority of DLBCL cases among pediatric transplant recipients (58%) were observed during the first year after transplantation. This time period alone contributed 4.41% of the general population cases.
Transplant recipients contributed a smaller proportion of BL diagnoses in the pediatric population (0.87%; 95% CI, 0.51%-1.23%; Table 4 ). Transplant recipients contributed a larger proportion of BL cases among girls (1.54%) than boys (0.65%), but the proportions did not vary noticeably across age groups (Table 4 ). The proportion of BL diagnoses contributed by transplant recipients increased across calendar time (0.43% in 1990-1994 and (2010) (2011) (2012) , during which only 0.39% of diagnoses were among transplant recipients because of a drop in the BL incidence rate among transplant recipients. All BL diagnoses in transplant recipients were observed among kidney, liver, and heart/lung recipients, and all diagnoses occurred more than a year after transplantation.
DISCUSSION
Although very few US children and adolescents have received a solid organ transplant, this population contributes a disproportionate fraction of pediatric NHL cases, especially DLBCL cases. This large contribution is due to the highly elevated risk of NHL after transplantation. The proportion of pediatric NHLs attributable to transplant recipients is growing over calendar time because transplant recipients are making up an increasing proportion of the pediatric population, although transplantation in this population remains rare. Moreover, most NHL diagnoses are made within the first year after transplantation and among very young children. NHL is one of the many cancers for which solid organ transplant recipients have a heightened risk. 3, 16 Immunosuppressant medications administered after transplantation are considered the primary cause of this increased risk, and reflecting this mechanism, most of the increase in the transplant population is from infectionrelated cancers. 16, 18 NHL cases are largely attributable to EBV infections that occur while recipients are immunosuppressed, as evidenced by the high prevalence of EBV detectable in NHL tumors and particularly in cases diagnosed during the heavily immunosuppressed period early after transplantation. 8, 9 Also reflecting this EBV-driven etiology, the most common NHL subtypes in our population were DLBCL and BL, 2 EBV-associated subtypes. Patients who experience a primary EBV infection after Abbreviation: CI, confidence interval. a Case numbers are based on the application of incidence rates observed within the Transplant Cancer Match study cancer registry areas to person-time estimates based on national data. Because of rounding to the nearest whole number, stratified case numbers may not add up to the estimated total case number in all instances. b Because these categories refer to the attained age and the attained calendar year, a recipient could contribute time to multiple categories across follow-up.
transplantation are particularly susceptible because transplant recipients have a higher NHL risk if they are seronegative for EBV before transplantation (this indicates that they can subsequently experience a primary infection). 9, 10 Children are especially vulnerable because, unlike adults, many have not been exposed to EBV before transplantation. 19 The proportion of pediatric NHLs in the US general population linked to transplantation differed across subgroups. These differences reflect the characteristics of recipient subgroups with a strongly elevated NHL risk and those making up a larger fraction of the transplant population. For instance, transplant recipients made up 4.5% of NHL diagnoses in children less than 5 years old. This higher proportion occurred because the youngest transplant recipients had the highest incidence of NHL (likely because of the greater susceptibility to a primary EBV infection in this population and because a larger proportion of the recipients were followed within 1 year of transplantation), whereas children less than 5 years old in the general population had a particularly low NHL incidence. Although male and female transplant recipients had similar NHL risk, girls contributed a larger proportion of NHL diagnoses because, in the general population, girls had a lower NHL risk than boys. In addition, most NHL diagnoses in transplant recipients occurred in the first year after transplantation because of the very high risk during this period. This high risk may be attributable to the high levels of immunosuppression administered at and early after transplantation. 20 As a result, this short time interval accounted for 1.4% of all US pediatric NHL cases. When NHL diagnoses were considered by the type of organ transplanted, most were contributed by kidney recipients because the kidney is the most frequently transplanted organ, but heart/lung recipients contributed the next highest proportion because the NHL risk is markedly elevated in this group.
Notably, we have found that the proportion of pediatric NHLs diagnosed in transplant recipients has been increasing with calendar time. This trend is driven by the rising prevalence of transplant recipients in the general population and not by increases in NHL risk among transplant recipients (Table 3) . Pediatric transplantation remains rare, but the rising number of living pediatric transplant recipients can be attributed to improvements in immunosuppression approaches, surgical techniques, and infectious disease control, which have led to increasing survival rates after transplantation. 15, 21, 22 Most NHLs diagnosed after transplantation were DLBCLs, and as a result, transplant cases made up a much larger fraction of the US pediatric DLBCL burden than the NHL burden overall. Remarkably, transplant recipients contributed 1 in 5 DLBCL cases diagnosed in children less than 5 years old and more than 1 in 10 cases across all ages in the most recent calendar years (2010) (2011) (2012) . In contrast, transplant recipients made up a considerably smaller proportion of the pediatric BL burden and contributed less than 1% of US cases. Some patterns of BL incidence in transplantation also differed from those for DLBCL. For example, although the majority of DLBCLs occurred within the first year after transplantation, all BL cases occurred after the first year. This is consistent with prior research showing that the BL incidence rises over time after transplantation. 23 Other patterns appeared consistent for DLBCL and BL. For instance, although DLBCL and BL were disproportionately diagnosed among boys in the general population, for both subtypes, the counts were more similar for boys and girls in the transplant population. Transplantation and its associated immunosuppression seem to be equalizers of sex differences in pediatric NHL risk.
Although transplant recipients made up a meaningful proportion of DLBCL and BL cases, this was not the case for all subtypes. Some NHL subtypes do not have a highly elevated risk in the setting of transplantation and immunosuppression, 13 and for these subtypes, the transplant population made little or no contribution to the population burden. For instance, no diagnoses of precursor cell lymphoblastic lymphoma were identified among pediatric recipients in our study, even though it is one of the most common subtypes in children. However, less than 1 case was expected on the basis of the size of the transplant population, so this does not necessarily represent a reduction in risk.
Childhood cancer is a major medical research priority, and NHL is among the most common childhood cancers. 24 Even though pediatric transplant recipients make up an important proportion of pediatric NHL cases, few studies have focused specifically on this population. NHL treatment approaches may be more complicated in transplant recipients because therapies directed at controlling the tumor may damage the graft or lead to rejection. 25, 26 It is yet unclear whether survival differs substantially between NHL patients with and without a solid organ transplant. 8, 9 In addition, because of the concentration of risk during a narrow time window in this small group, the pediatric transplant population would be a particularly good target for preventive interventions. Although an effective EBV vaccine or prophylaxis is not currently available, many pediatric recipients are monitored with serial measurements of circulating EBV viral load levels. 27 However, it is currently unclear whether changes to immunosuppressant regimens after EBV detection effectively prevent the development of NHL or the broader group of posttransplant lymphoproliferative disorders. 5, 28 This study is the first to estimate the impact of transplantation on the US burden of pediatric NHL. The TCM study provides reliable estimates of cancer incidence in transplant recipients because cases are identified through a linkage with cancer registries that verify diagnoses through standardized protocols. Linking with cancer registries is also advantageous because they have information on incident cancer diagnoses for the general population, and this provides a uniform method of cancer ascertainment. The geographic areas covered by the TCM study also capture a large representative sample of the overall US population.
Limitations should also be mentioned. First, only the DLBCL and BL subtypes were frequent enough to be evaluated individually. Nonetheless, the rarity of other subtypes in the pediatric transplant population suggests that their contribution to the overall US NHL counts would be minimal. In addition, we had information on the EBV status at transplantation for only 50% of the recipients, so we could not accurately estimate the degree to which EBV influences the burden of NHL contributed by transplant recipients. Also, although the TCM study linkage between the SRTR and cancer registries has high sensitivity, it can miss cancer diagnoses in transplant recipients, particularly among recipients who migrate out of the cancer registry catchment areas. 29 This will cause an underestimation of the NHL risk in transplant recipients, particularly in later years after transplantation, and result in an underestimation of the proportion of NHLs attributable to transplant recipients. Finally, the length of the follow-up time after transplantation available for most pediatric transplant recipients was somewhat short (median, 3.3 years). This partly reflects the reality of the current pediatric transplant recipient population because high rates of retransplantation and mortality after transplantation and the recency of many transplants have limited the time that these individuals have been at risk for NHL. However, a subset of recipients were lost to followup by SRTR, and this would have led to an underestimation of the NHL burden attributable to transplant recipients. Furthermore, the true contribution of transplant recipients to the US NHL burden may change in the future if recipients survive for longer time periods with their transplant.
In conclusion, transplant recipients contribute a substantial fraction of all NHL diagnoses (especially DLBCL diagnoses) in US children and adolescents. The proportion of NHL diagnoses attributable to transplant recipients has grown over time, and it is likely that this population will be an important source of pediatric NHL cases in the future. It would be beneficial for a portion of future efforts in pediatric lymphoma research to focus specifically on transplant recipients because this unique group may require prevention and treatment approaches that differ from those for the general population. EBV prevention or treatment targeted toward this group could potentially lead to measureable reductions in the pediatric NHL incidence overall.
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